Study ID,Country,N of centers ,Setting,Sponsor,Followup duration,Comparison ,Number randomized,Age,Women (%),Bacteremia (%)
Daneman N 2024,"Multinational
",74,Hospital,Academic,13 weeks,7 days,NR,NR,NR,100%
,,,,,,14 days ,,,,
Lafaurie M 2023,France,27,Hospital,Academic,12 weeks,7 days,115,62.3 (49.9â€“73.2)â˜¨,0%,15.60%
,,,,,,14 days ,125,58.9 (49.3â€“72.5)â˜¨,,18%
Molina J 2022*,Spain,5,Mixed,Academic,4 weeks,7 days,70**,NR,NR,100%
,,,,,,14 days ,66**,,,
von Dach E 2020*,Switzerland,3,Hospital,Academic,13 weeks,7 days,107**,NR,NR,100%
,,,,,,14 days ,117**,,,
Yahav D 2019,Multinational,3,Hospital,Academic,13 weeks,7 days,212**,71 (61.8â€“81)â˜¨,51%,100%
,,,,,,14 days,199*,71 (61â€“80)â˜¨,54.70%,
Rudrabhatla P 2018,India,1,Hospital,Academic,6 weeks,7 days,27,51(42-60)â˜¨,59%,NR
,,,,,,14 days ,27,55 (42-60)â˜¨,52%,
Dinh A 2017,France,10,Mixed,Academic,4 weeks,5 days,49,30.5 Â± 10.3â˜¨â˜¨,100%,2.30%
,,,,,,10 days,51,33.1 Â± 11.7â˜¨â˜¨,,4.40%
van Nieuwkoop C 2017,Netherlands,6,Mixed,Academic,12 weeks,7 days,97,60 (48â€“72)â˜¨,55%,23%
,,,,,,14 days ,103,61(40â€“73)â˜¨,59%,15%
Ren H 2017 ,China,16,Mixed,Academic,1.5-2 weeks,5 days ,165,49.08 Â± 17.37â˜¨â˜¨,88.61%,NR
,,,,,,7-14 days ,165,50.18 Â± 17.42â˜¨â˜¨,86.16%,
Sandberg T 2012,Sweeden,21,Mixed,Pharma,9 weeks,7 days,126,46 (27â€“62)â˜¨,100%,22%
,,,,,,14 days,122,41(23â€“58)â˜¨,,32%
Peterson J 2008,United States,113,Mixed,Pharma,6.5 weeks,5 days,559,54.2 Â± 17.42â˜¨â˜¨,61.50%,NR
,,,,,,10 days,543,,60.40%,
Klausner H 2007,United States,130,Mixed,Pharma,5.5-6.5 weeks ,5 days,146,38.9 Â± 17.96â˜¨â˜¨,94.50%,8.20%
,,,,,,10 days,165,39.4 Â± 17.05â˜¨â˜¨,97.60%,7.30%
Ulleryd P 2003,Sweden,1,Hospital,Pharma,52 weeks,14 days,57,61 (18â€“85)â˜¨,0%,18%
,,,,,,28 days,57,62 (30â€“77)â˜¨,,9%
Mensa J 1999,Spain,1,Hospital,NR,4-6 weeks,7 days,153,44 (NR),100%,29%
,,,,,,14 days ,151,,,
de Gier R 1995,Netherlands,3,Hospital,Pharma,4-6 weeks,7 days,26,68 (36-87)â˜¨â˜¨â˜¨,77%,NR
,,,,,,14 days,28,67 (23-94)â˜¨â˜¨â˜¨,57%,
Jernelius H 1988,Sweeden,1,Mixed,Pharma,3-4 weeks,7 days,38,59 (18-81)â˜¨â˜¨â˜¨,62.50%,15.60%
,,,,,,21 days,39,61 (16-78)â˜¨â˜¨â˜¨,75.80%,13.70%
,,,,,,,,,,
"Abbreviations - ID: Identification; NR: Not reported; N: Number
NR - No data on patient characteristics of UTI subgroup out of all bacteremia patients  
* Only number of patients with pyelonephritis evaluated reported from a trial on patients with bacteremia
**Data on the number of randomized patients with pyelonephritis was received from the authors
? Age data presented as median (IQR range) 
?? Age data presented as mean?±?SD
??? Age data presented as mean (range)",,,,,,,,,,
